학술논문
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
Document Type
article
Author
Li Wang; Markus H. Kainulainen; Nannan Jiang; Han Di; Gaston Bonenfant; Lisa Mills; Michael Currier; Punya Shrivastava-Ranjan; Brenda M. Calderon; Mili Sheth; Brian R. Mann; Jaber Hossain; Xudong Lin; Sandra Lester; Elizabeth A. Pusch; Joyce Jones; Dan Cui; Payel Chatterjee; M. Harley Jenks; Esther K. Morantz; Gloria P. Larson; Masato Hatta; Jennifer L. Harcourt; Azaibi Tamin; Yan Li; Ying Tao; Kun Zhao; Kristine Lacek; Ashley Burroughs; Wei Wang; Malania Wilson; Terianne Wong; So Hee Park; Suxiang Tong; John R. Barnes; Mark W. Tenforde; Wesley H. Self; Nathan I. Shapiro; Matthew C. Exline; D. Clark Files; Kevin W. Gibbs; David N. Hager; Manish Patel; Alison L. Halpin; Laura K. McMullan; Justin S. Lee; Hongjie Xia; Xuping Xie; Pei-Yong Shi; C. Todd Davis; Christina F. Spiropoulou; Natalie J. Thornburg; M. Steven Oberste; Vivien G. Dugan; SSEV Bioinformatics Working Group; David E. Wentworth; Bin Zhou
Source
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Subject
Language
English
ISSN
2041-1723
Abstract
Emerging SARS-CoV-2 variants raise concerns on immune evasion. Here, the authors evaluate the neutralization efficiency of COVID-19 mRNA vaccinee sera against representative viruses of 13 WHO-designated SARS-CoV-2 variants of concern/interest.